Molecular and biological mechanisms of bone metastasis

EAU Update Series

Volumn 3, Issue 4, 2005, Pages 214-226

  Cecchini, Marco G ^a   Wetterwald, Antoinette ^a   van der Pluijm, Gabri ^b   Thalmann, George N ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bisphosphonate; Bone metastasis; Mammary cancer; Osteoblast; Osteoclast; Osteolysis; Osteosclerosis; Prostate cancer

Indexed keywords

ATRASENTAN; BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR ANTIBODY;

ANTINEOPLASTIC ACTIVITY; BONE MARROW METASTASIS; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CARCINOGENESIS; CAUSE OF DEATH; CELL FUNCTION; CELL SURVIVAL; CLINICAL TRIAL; GENE EXPRESSION; HEMATOPOIESIS; HISTOPATHOLOGY; HORMONE DEPENDENCE; HUMAN; MICROENVIRONMENT; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; OSTEOSCLEROSIS; PROSTATE CANCER; REVIEW;

EID: 28444484968     PISSN: 15709124     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euus.2005.09.006     Document Type: Article

References (175)

1. I.J. Fidler Critical determinants of cancer metastasis: Rationale for therapy Cancer Chemother Pharmacol 43 Suppl. 1999 S3-S10
2. A.F. Chambers G.N. Naumov H.J. Varghese K.V. Nadkarni I.C. MacDonald A.C. Groom Critical steps in hematogenous metastasis: An overview Surg Oncol Clin N Am 10 2 2001 243-255 vii
3. T.P. Butler P.M. Gullino Quantitation of cell shedding into efferent blood of mammary adenocarcinoma Cancer Res 35 3 1975 512-516
4. 125 I-5-iodo-2′-deoxyuridine J Natl Cancer Inst 45 4 1970 773-782
5. L. Weiss Metastatic inefficiency Adv Cancer Res 54 1990 159-211
6. K.J. Luzzi I.C. MacDonald E.E. Schmidt N. Kerkvliet V.L. Morris A.F. Chambers Multistep nature of metastatic inefficiency: Dormancy of solitary cells after successful extravasation and limited survival of early micrometastases Am J Pathol 153 3 1998 865-873
7. M.D. Cameron E.E. Schmidt N. Kerkvliet K.V. Nadkarni V.L. Morris A.C. Groom et al. Temporal progression of metastasis in lung: Cell survival, dormancy, and location dependence of metastatic inefficiency Cancer Res 60 9 2000 2541-2546
8. G. van der Pluijm I. Queue B. Sijmons J.T. Buijs Löwik CWGM A. Wetterwald et al. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo Cancer Res. 65 17 2005 7682-7690
9. A.F. Chambers A.C. Groom I.C. MacDonald Dissemination and growth of cancer cells in metastatic sites Nat Rev Cancer 2 8 2002 563-572
10. Arguello F, Cohen HJ. Structural and microenvironmental bone marrow factors involved in the pathogenesis of bone metastasis, in Bone metastasis-mechanisms and pathophysiology, F.W.a.S. Orr, G., Editor. 1996. R.G. Landers Company: Austin. p. 31-45.
11. O.V. Batson The function of the vertebral veins and their role in the spread of metastasis Ann Surg 112 1940 138-149
12. L.M. Franks The spread of prostatic carcinoma to the bones J Pathol Bacteriol 66 1 1953 91-93
13. D.H. Shevrin S.C. Kukreja L. Ghosh T.E. Lad Development of skeletal metastasis by human prostate cancer in athymic nude mice Clin Exp Metastasis 6 5 1988 401-409
14. G.N. Thalmann P.E. Anezinis S.M. Chang H.E. Zhau E.E. Kim V.L. Hopwood et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer Cancer Res 54 10 1994 2577-2581
15. R.A. Willis Secondary tumors of bone in The spread of tumors in the human body 1973 Butterworth Co. London 229-250
16. B.A. Berrettoni J.R. Carter Mechanisms of cancer metastasis to bone J Bone Joint Surg Am 68 2 1986 308-312
17. S. Paget The distribution of secondary growths in cancer of the breast Lancet 1 1889 571-573
18. G.P. Gupta J. Massague Platelets and metastasis revisited: A novel fatty link J Clin Invest 114 12 2004 1691-1693
19. T.A. Springer Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm Cell 76 2 1994 301-314
20. C. Page M. Rose M. Yacoub R. Pigott Antigenic heterogeneity of vascular endothelium Am J Pathol 141 3 1992 673-683
21. C. Garlanda E. Dejana Heterogeneity of endothelial cells. Specific markers Arterioscler Thromb Vasc Biol 17 7 1997 1193-1202
22. C.R. Cooper C.H. Chay J.D. Gendernalik H.L. Lee J. Bhatia R.S. Taichman et al. Stromal factors involved in prostate carcinoma metastasis to bone Cancer 97 3 Suppl. 2003 739-747
23. T. Yoneda T. Hiraga Crosstalk between cancer cells and bone microenvironment in bone metastasis Biochem Biophys Res Commun 328 3 2005 679-687
24. K.M. Schweitzer A.M. Drager P. van der Valk S.F. Thijsen A. Zevenbergen A.P. Theijsmeijer et al. Constitutive expression of E-selectin and vascular cell adhesion molecule-1 on endothelial cells of hematopoietic tissues Am J Pathol 148 1 1996 165-175
25. K. Jacobsen J. Kravitz P.W. Kincade D.G. Osmond Adhesion receptors on bone marrow stromal cells: In vivo expression of vascular cell adhesion molecule-1 by reticular cells and sinusoidal endothelium in normal and gamma-irradiated mice Blood 87 1 1996 73-82
26. I.B. Mazo U.H. von Andrian Adhesion and homing of blood-borne cells in bone marrow microvessels J Leukoc Biol 66 1 1999 25-32
27. M. Tavassoli J.J. Minguell Homing of hemopoietic progenitor cells to the marrow Proc Soc Exp Biol Med 196 4 1991 367-373
28. C.L. Hardy The homing of hematopoietic stem cells to the bone marrow Am J Med Sci 309 5 1995 260-266
29. T. Lapidot A. Dar O. Kollet How do stem cells find their way home? Blood 2005
30. C.J. Dimitroff M. Lechpammer D. Long-Woodward J.L. Kutok Rolling of human bone-metastatic prostate tumor cells on human bone marrow endothelium under shear flow is mediated by E-selectin Cancer Res 64 15 2004 5261-5269
31. C.J. Dimitroff L. Descheny N. Trujillo R. Kim V. Nguyen W. Huang et al. Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells Cancer Res 65 13 2005 5750-5760
32. D.A. Sipkins X. Wei J.W. Wu J.M. Runnels D. Cote T.K. Means et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment Nature 435 7044 2005 969-973
33. R. Mohle F. Bautz C. Denzlinger L. Kanz Transendothelial migration of hematopoietic progenitor cells. Role of chemotactic factors Ann N Y Acad Sci 938 2001 26-34
34. Y.X. Sun A. Schneider Y. Jung J. Wang J. Dai K. Cook et al. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo J Bone Miner Res 20 2 2005 318-329
35. T. Nagasawa A chemokine, SDF-1/PBSF, and its receptor, CXC chemokine receptor 4, as mediators of hematopoiesis Int J Hematol 72 4 2000 408-411
36. T. Lapidot O. Kollet The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice Leukemia 16 10 2002 1992-2003
37. A. Muller B. Homey H. Soto N. Ge D. Catron M.E. Buchanan et al. Involvement of chemokine receptors in breast cancer metastasis Nature 410 6824 2001 50-56
38. R.S. Taichman C. Cooper E.T. Keller K.J. Pienta N.S. Taichman L.K. McCauley Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone Cancer Res 62 6 2002 1832-1837
39. F. Balkwill Cancer and the chemokine network Nat Rev Cancer 4 7 2004 540-550
40. L.A. Liotta An attractive force in metastasis Nature 410 6824 2001 24-25
41. C.K. Miranti J.S. Brugge Sensing the environment: A historical perspective on integrin signal transduction Nat Cell Biol 4 4 2002 E83-E90
42. W. Guo F.G. Giancotti Integrin signalling during tumour progression Nat Rev Mol Cell Biol 5 10 2004 816-826
43. P. Clezardin Recent insights into the role of integrins in cancer metastasis Cell Mol Life Sci 54 6 1998 541-548
44. I. Pecheur O. Peyruchaud C.M. Serre J. Guglielmi C. Voland F. Bourre et al. Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone Faseb J 16 10 2002 1266-1268
45. J.F. Harms D.R. Welch R.S. Samant L.A. Shevde M.E. Miele G.R. Babu et al. A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis Clin Exp Metastasis 21 2 2004 119-128
46. A. Boucharaba C.M. Serre S. Gres J.S. Saulnier-Blache J.C. Bordet J. Guglielmi et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer J Clin Invest 114 12 2004 1714-1725
47. M. Edlund T. Miyamoto R.A. Sikes R. Ogle G.W. Laurie M.C. Farach-Carson et al. Integrin expression and usage by prostate cancer cell lines on laminin substrata Cell Growth Differ 12 2 2001 99-107
48. H. Nemoto S.R. Rittling H. Yoshitake K. Furuya T. Amagasa K. Tsuji et al. Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues J Bone Miner Res 16 4 2001 652-659
49. J.H. Zhang J. Wang J. Tang B. Barnett J. Dickson N. Hahsimoto et al. Bone sialoprotein promotes bone metastasis of a non-bone-seeking clone of human breast cancer cells Anticancer Res 24 3a 2004 1361-1368
50. G.N. Thalmann R.A. Sikes R.E. Devoll J.A. Kiefer R. Markwalder I. Klima et al. Osteopontin: Possible role in prostate cancer progression Clin Cancer Res 5 8 1999 2271-2277
51. P.S. Rudland A. Platt-Higgins M. El-Tanani S. De Silva Rudland R. Barraclough J.H. Winstanley et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer Cancer Res 62 12 2002 3417-3427
52. H. Adwan T.J. Bauerle M.R. Berger Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells Cancer Gene Ther 11 2 2004 109-120
53. U. Gunthert M. Hofmann W. Rudy S. Reber M. Zoller I. Haussmann et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells Cell 65 1 1991 13-24
54. G.F. Weber S. Ashkar M.J. Glimcher H. Cantor Receptor-ligand interaction between CD44 and osteopontin (Eta-1) Science 271 5248 1996 509-512
55. A. Hill S. McFarlane P.G. Johnston D.J. Waugh The emerging role of CD44 in regulating skeletal micrometastasis Cancer Lett 2005
56. R. Zohar N. Suzuki K. Suzuki P. Arora M. Glogauer C.A. McCulloch et al. Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration J Cell Physiol 184 1 2000 118-130
57. M.A. Chellaiah K.A. Hruska The integrin alpha(v)beta(3) and CD44 regulate the actions of osteopontin on osteoclast motility Calcif Tissue Int 72 3 2003 197-205
58. E. Medico A. Gentile C. Lo Celso T.A. Williams G. Gambarotta L. Trusolino et al. Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth Cancer Res 61 15 2001 5861-5868
59. M. Kucia R. Reca K. Miekus J. Wanzeck W. Wojakowski A. Janowska-Wieczorek et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: Pivotal role of the SDF-1-CXCR4 Axis Stem Cells 2005
60. L.A. Liotta E.C. Kohn The microenvironment of the tumour-host interface Nature 411 6835 2001 375-379
61. I.J. Fidler The organ microenvironment and cancer metastasis Differentiation 70 9-10 2002 498-505
62. G.R. Mundy Metastasis to bone: Causes, consequences and therapeutic opportunities Nat Rev Cancer 2 8 2002 584-593
63. E.T. Keller J. Zhang C.R. Cooper P.C. Smith L.K. McCauley K.J. Pienta et al. Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone Cancer Metastasis Rev 20 3-4 2001 333-349
64. G.D. Roodman Mechanisms of bone metastasis N Engl J Med 350 16 2004 1655-1664
65. T.M. Dexter E. Spooncer P. Simmons T.D. Allen Long-term bone marrow culture: An overview of techniques and experience In: D.G. Wright J.S. Greenberger editors. Long-term bone marrow culture 1984 Alan R. Liss, Inc. New-York 57-96
66. B. Heissig Y. Ohki Y. Sato S. Rafii Z. Werb K. Hattori A role for niches in hematopoietic cell development Hematology 10 3 2005 247-253
67. E.F. Eriksen D.W. Axelrod F. Melsen Bone histomorphometry 1994 Raven Press New York p. 3-12
68. W. Hofstetter R. Felix M.G. Cecchini In: J.P. Bilezikian L.G. Raisz G.A. Rodan editors. Colony-stimulating factors, in Principles of bone biolgy 1996 Academic Press San Diego 673-686
69. D.L. Lacey E. Timms H.L. Tan M.J. Kelley C.R. Dunstan T. Burgess et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 2 1998 165-176
70. H. Yasuda N. Shima N. Nakagawa K. Yamaguchi M. Kinosaki S. Mochizuki et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Proc Natl Acad Sci USA 95 7 1998 3597-3602
71. W.S. Simonet D.L. Lacey C.R. Dunstan M. Kelley M.S. Chang R. Luthy et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density Cell 89 2 1997 309-319
72. H. Yasuda N. Shima N. Nakagawa S.I. Mochizuki K. Yano N. Fujise et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro Endocrinology 139 3 1998 1329-1337
73. K. Tsukii N. Shima S. Mochizuki K. Yamaguchi M. Kinosaki K. Yano et al. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha, 25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone Biochem Biophys Res Commun 246 2 1998 337-341
74. L.C. Hofbauer A.E. Heufelder Osteoprotegerin and its cognate ligand: A new paradigm of osteoclastogenesis Eur J Endocrinol 139 2 1998 152-154
75. B.F. Boyce T. Yamashita Z. Yao Q. Zhang F. Li L. Xing Roles for NF-kappaB and c-Fos in osteoclasts J Bone Miner Metab 23 Suppl. 2005 11-15
76. P.V. Hauschka A.E. Mavrakos M.D. Iafrati S.E. Doleman M. Klagsbrun Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose J Biol Chem 261 27 1986 12665-12674
77. J. Pfeilschifter G.R. Mundy Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones Proc Natl Acad Sci USA 84 7 1987 2024-2028
78. A. Schneider L.M. Kalikin A.C. Mattos E.T. Keller M.J. Allen K.J. Pienta et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton Endocrinology 146 4 2005 1727-1736
79. F. Arguello R.B. Baggs B.T. Graves S.E. Harwell H.J. Cohen C.N. Frantz Effect of IL-1 on experimental bone/bone-marrow metastases Int J Cancer 52 5 1992 802-827
80. B. Krempien I.J. Diel B. Jöckle-Kretz R. Büchele L. Andre The Walker Carcinomasarcoma 256 as an experimental model of bone metastasis. Influence of skeletal metabolism on the development of bone metastases Verh Dtsch Ges Pathol 68 1984 211-216
81. J.E. Brown C.S. Thomson S.P. Ellis S.A. Gutcher O.P. Purohit R.E. Coleman Bone resorption predicts for skeletal complications in metastatic bone disease Br J Cancer 89 11 2003 2031-2037
82. R.E. Coleman P. Major A. Lipton J.E. Brown K.A. Lee M. Smith et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the Bisphosphonate Zoledronic Acid J Clin Oncol 2005
83. K.B. Michels F. Xue L. Brandt A. Ekbom Hyperparathyroidism and subsequent incidence of breast cancer Int J Cancer 110 3 2004 449-451
84. M.R. Smith Osteoporosis during androgen deprivation therapy for prostate cancer Urology 60 3 Suppl 1 2002 79-85
85. E.S. Orwoll R.F. Klein Osteoporosis in men Endocr Rev 16 1 1995 87-116
86. G.M. Sundkvist L. Ahlgren B. Lilja S. Mattsson Quantitative bone scintigraphy in prostatic carcinoma-long-term response to treatment Nuklearmedizin 32 5 1993 231-235
87. S.S. Padalecki M. Carreon B. Grubbs Y. Cui T.A. Guise Androgen deprivation enhances bone loss and prostate cancer metastasis to bone: prevention by zoledronic acid Oncology 17 2003 32
88. P. Garnero Markers of bone turnover in prostate cancer Cancer Treat Rev 27 3 2001 187-192
89. R.S. Taichman Blood and bone: Two tissues whose fates are intertwined to create the hematopoietic stem-cell niche Blood 105 7 2005 2631-2639
90. J. Zhang C. Niu L. Ye H. Huang X. He W.G. Tong et al. Identification of the haematopoietic stem cell niche and control of the niche size Nature 425 6960 2003 836-841
91. L.M. Calvi G.B. Adams K.W. Weibrecht J.M. Weber D.P. Olson M.C. Knight et al. Osteoblastic cells regulate the haematopoietic stem cell niche Nature 425 6960 2003 841-846
92. G. Prindull Hypothesis: Cell plasticity, linking embryonal stem cells to adult stem cell reservoirs and metastatic cancer cells? Exp Hematol 33 7 2005 738-746
93. S.M. Tu S.H. Lin C.J. Logothetis Stem-cell origin of metastasis and heterogeneity in solid tumours Lancet Oncol 3 8 2002 508-513
94. R.E. Coleman J.J. Seaman The role of zoledronic acid in cancer: Clinical studies in the treatment and prevention of bone metastases Semin Oncol 28 2 Suppl 6 2001 11-16
95. S.A. Charhon M.C. Chapuy E.E. Delvin A. Valentin-Opran C.M. Adouard P.J. Meunier Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia Cancer 51 1983 918-924
96. N.W. Clarke J. McClure N.J. George Osteoblast function and osteomalacia in metastatic prostate cancer Eur Urol 24 2 1993 286-290
97. D.R. Clohisy M.L. Ramnaraine Osteoclasts are required for bone tumors to grow and destroy bone J Orthop Res 16 6 1998 660-666
98. J. Southby M.W. Kissin J.A. Danks J.A. Hayman J.M. Moseley M.A. Henderson et al. Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer Cancer Res 50 23 1990 7710-7716
99. J.A. Danks P.R. Ebeling J.A. Hayman H. Diefenbach-Jagger F.M. Collier V. Grill et al. Immunohistochemical localization of parathyroid hormone-related protein in parathyroid adenoma and hyperplasia J Pathol 161 1 1990 27-33
100. M. Henderson J. Danks J. Moseley J. Slavin T. Harris M. McKinlay et al. Parathyroid hormone-related protein production by breast cancers, improved survival, and reduced bone metastases J Natl Cancer Inst 93 3 2001 234-237
101. T. Miki S. Yano M. Hanibuchi S. Sone Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice Oncol Res 12 5 2000 209-217
102. G.J. Powell J. Southby J.A. Danks R.G. Stillwell J.A. Hayman M.A. Henderson et al. Localization of parathyroid hormone-related protein in breast cancer metastases: Increased incidence in bone compared with other sites Cancer Res 51 11 1991 3059-3061
103. N. Kohno S. Kitazawa M. Fukase Y. Sakoda Y. Kanbara Y. Furuya et al. The expression of parathyroid hormone-related protein in human breast cancer with skeletal metastases Surg Today 24 3 1994 215-220
104. S.J. Vargas M.T. Gillespie G.J. Powell J. Southby J.A. Danks J.M. Moseley et al. Localization of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesions by in situ hybridization J Bone Miner Res 7 8 1992 971-979
105. T.A. Guise J.J. Yin S.D. Taylor Y. Kumagai M. Dallas B.F. Boyce et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis J Clin Invest 98 7 1996 1544-1549
106. J.J. Yin K. Selander J.M. Chirgwin M. Dallas B.G. Grubbs R. Wieser et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development J Clin Invest 103 2 1999 197-206
107. M.S. Bendre D.C. Montague T. Peery N.S. Akel D. Gaddy L.J. Suva Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease Bone 33 1 2003 28-37
108. J.E. De Larco B.R. Wuertz K.A. Rosner S.A. Erickson D.E. Gamache J.C. Manivel et al. A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells Am J Pathol 158 2 2001 639-646
109. C.J. Logothetis S.H. Lin Osteoblasts in prostate cancer metastasis to bone Nat Rev Cancer 5 1 2005 21-28
110. T. Komori H. Yagi S. Nomura A. Yamaguchi K. Sasaki K. Deguchi et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts Cell 89 5 1997 755-764
111. F. Otto A.P. Thornell T. Crompton A. Denzel K.C. Gilmour I.R. Rosewell et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development Cell 89 5 1997 765-771
112. P. Ducy R. Zhang V. Geoffroy A.L. Ridall G. Karsenty Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation Cell 89 5 1997 747-754
113. K. Nakashima X. Zhou G. Kunkel Z. Zhang J.M. Deng R.R. Behringer et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation Cell 108 1 2002 17-29
114. K. Orford C. Crockett J.P. Jensen A.M. Weissman S.W. Byers Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin J Biol Chem 272 40 1997 24735-24738
115. S.E. Harris L.F. Bonewald M.A. Harris M. Sabatini S. Dallas J.Q. Feng et al. Effects of transforming growth factor beta on bone nodule formation and expression of bone morphogenetic protein 2, osteocalcin, osteopontin, alkaline phosphatase, and type I collagen mRNA in long-term cultures of fetal rat calvarial osteoblasts J Bone Miner Res 9 6 1994 855-863
116. H. Marquardt M.N. Lioubin T. Ikeda Complete amino acid sequence of human transforming growth factor type beta 2 J Biol Chem 262 25 1987 12127-12131
117. D. Chen M. Zhao G.R. Mundy Bone morphogenetic proteins Growth Factors 22 4 2004 233-241
118. M. Yanagisawa H. Kurihara S. Kimura Y. Tomobe M. Kobayashi Y. Mitsui et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells Nature 332 6163 1988 411-415
119. Y. Takuwa T. Masaki K. Yamashita The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae Biochem Biophys Res Commun 170 3 1990 998-1005
120. H. Tsukahara C. Hori M. Hiraoka K. Yamamoto Y. Ishii M. Mayumi Endothelin subtype A receptor antagonist induces osteopenia in growing rats Metabolism 47 11 1998 1403-1407
121. J.B. Nelson S.H. Nguyen J.R. Wu-Wong T.J. Opgenorth D.B. Dixon L.W. Chung et al. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade Urology 53 5 1999 1063-1069
122. J.B. Nelson S.P. Hedican D.J. George A.H. Reddi S. Piantadosi M.A. Eisenberger et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate Nat Med 1 9 1995 944-949
123. J.J. Yin K.S. Mohammad S.M. Kakonen S. Harris J.R. Wu-Wong J.L. Wessale et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases Proc Natl Acad Sci USA 100 19 2003 10954-10959
124. L.M. Boyden J. Mao J. Belsky L. Mitzner A. Farhi M.A. Mitnick et al. High bone density due to a mutation in LDL-receptor-related protein 5 N Engl J Med 346 20 2002 1513-1521
125. M. Kato M.S. Patel R. Levasseur I. Lobov B.H. Chang D.A. Glass II et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor J Cell Biol 157 2 2002 303-314
126. R.D. Little J.P. Carulli R.G. Del Mastro J. Dupuis M. Osborne C. Folz et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait Am J Hum Genet 70 1 2002 11-19
127. J.R. Hens K.M. Wilson P. Dann X. Chen M.C. Horowitz J.J. Wysolmerski TOPGAL Mice Show That the Canonical Wnt Signaling Pathway Is Active During Bone Development and Growth and Is Activated by Mechanical Loading In Vitro J Bone Miner Res 20 7 2005 1103-1113
128. C.A. Gregory W.G. Gunn E. Reyes A.J. Smolarz J. Munoz J.L. Spees et al. How wnt signaling affects bone repair by mesenchymal stem cells from the bone marrow Ann N Y Acad Sci 1049 2005 97-106
129. N.H. Kulkarni D.L. Halladay R.R. Miles L.M. Gilbert C.A. Frolik R.J. Galvin et al. Effects of parathyroid hormone on Wnt signaling pathway in bone J Cell Biochem 2005
130. G. Chen N. Shukeir A. Potti K. Sircar A. Aprikian D. Goltzman et al. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: Potential pathogenetic and prognostic implications Cancer 101 6 2004 1345-1356
131. H. Zhu M. Mazor Y. Kawano M.M. Walker H.Y. Leung K. Armstrong et al. Analysis of Wnt gene expression in prostate cancer: Mutual inhibition by WNT11 and the androgen receptor Cancer Res 64 21 2004 7918-7926
132. E. Tian F. Zhan R. Walker E. Rasmussen Y. Ma B. Barlogie et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma N Engl J Med 349 26 2003 2483-2494
133. J. Dai Y. Kitagawa J. Zhang Z. Yao A. Mizokami S. Cheng et al. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein Cancer Res 64 3 2004 994-999
134. H.P. Gerber T.H. Vu A.M. Ryan J. Kowalski Z. Werb N. Ferrara VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation Nat Med 5 6 1999 623-628
135. M.H. Lee Y.J. Kim H.J. Kim H.D. Park A.R. Kang H.M. Kyung et al. BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression J Biol Chem 278 36 2003 34387-34394
136. K.S. Lee H.J. Kim Q.L. Li X.Z. Chi C. Ueta T. Komori et al. Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12 Mol Cell Biol 20 23 2000 8783-8792
137. H.J. Kim J.H. Kim S.C. Bae J.Y. Choi H.M. Ryoo The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2 J Biol Chem 278 1 2003 319-326
138. H. Lilja Biology of prostate-specific antigen Urology 62 5 Suppl. 1 2003 27-33
139. S.D. Cramer Z. Chen D.M. Peehl Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts J Urol 156 2 Pt 1 1996 526-531
140. M. Iwamura J. Hellman A.T. Cockett H. Lilja S. Gershagen Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen Urology 48 2 1996 317-325
141. P. Cohen D.M. Peehl H.C. Graves R.G. Rosenfeld Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease J Endocrinol 142 3 1994 407-415
142. M. Koutsilieris Osteoblastic metastasis in advanced prostate cancer Anticancer Res 13 2 1993 443-449
143. S.A. Rabbani J. Desjardins A.W. Bell D. Banville A. Mazar J. Henkin et al. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells Biochem Biophys Res Commun 173 3 1990 1058-1064
144. H. Fleisch Bisphosphonates: Mechanisms of action Endocr Rev 19 1 1998 80-100
145. C.M. Shipman M.J. Rogers J.F. Apperley R.G. Russell P.I. Croucher Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity Br J Haematol 98 3 1997 665-672
146. S.G. Senaratne G. Pirianov J.L. Mansi T.R. Arnett K.W. Colston Bisphosphonates induce apoptosis in human breast cancer cell lines Br J Cancer 82 8 2000 1459-1468
147. M.V. Lee E.M. Fong F.R. Singer R.S. Guenette Bisphosphonate treatment inhibits the growth of prostate cancer cells Cancer Res 61 6 2001 2602-2608
148. S. Boissier S. Magnetto L. Frappart B. Cuzin F.H. Ebetino P.D. Delmas et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices Cancer Res 57 18 1997 3890-3894
149. G. van der Pluijm H. Vloedgraven E. van Beek L. van der Wee-Pals C. Lowik S. Papapoulos Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro J Clin Invest 98 3 1996 698-705
150. P. Heikkila O. Teronen M. Moilanen Y.T. Konttinen R. Hanemaaijer M. Laitinen et al. Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines Anticancer Drugs 13 3 2002 245-254
151. O. Teronen P. Heikkila Y.T. Konttinen M. Laitinen T. Salo R. Hanemaaijer et al. MMP inhibition and downregulation by bisphosphonates Ann NY Acad Sci 878 1999 453-465
152. S. Boissier M. Ferreras O. Peyruchaud S. Magnetto F.H. Ebetino M. Colombel et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases Cancer Res 60 11 2000 2949-2954
153. S.S. Virtanen H.K. Vaananen P.L. Harkonen P.T. Lakkakorpi Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway Cancer Res 62 9 2002 2708-2714
154. J. Wood K. Bonjean S. Ruetz A. Bellahcene L. Devy J.M. Foidart et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid J Pharmacol Exp Ther 302 3 2002 1055-1061
155. P. Fournier S. Boissier S. Filleur J. Guglielmi F. Cabon M. Colombel et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats Cancer Res 62 22 2002 6538-6544
156. P. Clezardin P. Fournier S. Boissier O. Peyruchaud In vitro and in vivo antitumor effects of bisphosphonates Curr Med Chem 10 2 2003 173-180
157. J.R. Green Bisphosphonates in cancer therapy Curr Opin Oncol 14 6 2002 609-615
158. T. Hiraga P.J. Williams G.R. Mundy T. Yoneda The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases Cancer Res 61 11 2001 4418-4424
159. A. Sasaki B.F. Boyce B. Story K.R. Wright M. Chapman R. Boyce et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice Cancer Res 55 16 1995 3551-3557
160. D.G. Hall G. Stoica Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system J Bone Miner Res 9 2 1994 221-230
161. B. Krempien C. Manegold Prophylactic treatment of skeletal metastases, tumor induced osteolysis, and hypercalcemia in rats with the bisphosphonate Cl2MBP Cancer 72 1993 91-98
162. B. Krempien F. Wingen T. Eichmann M. Müller D. Schmähl Protective effect of a prophylactic treatment with the bisphosphonate 3-amino-1-hydroxypropane-1,1 bisphosphonic acid on the development of tumor osteopahthies in rat: Experimental studies with the Walker Carcinosarcoma 256 Oncology 45 41-6 1988
163. M. Edinger T.J. Sweeney A.A. Tucker A.B. Olomu R.S. Negrin C.H. Contag Noninvasive assessment of tumor cell proliferation in animal models Neoplasia 1 4 1999 303-310
164. A.H. Paterson T.J. Powles J.A. Kanis E. McCloskey J. Hanson S. Ashley Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer J Clin Oncol 11 1 1993 59-65
165. G.N. Hortobagyi R.L. Theriault L. Porter D. Blayney A. Lipton C. Sinoff et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group N Engl J Med 335 24 1996 1785-1791
166. A.T. van Holten-Verzantvoort H.M. Kroon O.L. Bijvoet F.J. Cleton L.V. Beex G. Blijham et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer J Clin Oncol 11 3 1993 491-498
167. J.R. Berenson A. Lichtenstein L. Porter M.A. Dimopoulos R. Bordoni S. George et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group N Engl J Med 334 8 1996 488-493
168. J.R. Berenson A. Lichtenstein L. Porter M.A. Dimopoulos R. Bordoni S. George et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group J Clin Oncol 16 2 1998 593-602
169. J.A. Kanis T. Powles A.H. Paterson E.V. McCloskey S. Ashley Clodronate decreases the frequency of skeletal metastases in women with breast cancer Bone 19 6 1996 663-667
170. P.F. Conte J. Latreille L. Mauriac F. Calabresi R. Santos D. Campos et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group J Clin Oncol 14 9 1996 2552-2559
171. A.T. van Holten-Verzantvoort J. Hermans L.V. Beex G. Blijham F.J. Cleton B.C. van Eck-Smit et al. Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? Eur J Cancer 32A 3 1996 450-454
172. T. Powles S. Paterson J.A. Kanis E. McCloskey S. Ashley A. Tidy et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer J Clin Oncol 20 15 2002 3219-3224
173. I.J. Diel E.F. Solomayer S.D. Costa C. Gollan R. Goerner D. Wallwiener et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment N Engl J Med 339 6 1998 357-363
174. T. Saarto C. Blomqvist P. Virkkunen I. Elomaa Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial J Clin Oncol 19 1 2001 10-17
175. M.A. Carducci R.J. Padley J. Breul N.J. Vogelzang B.A. Zonnenberg D.D. Daliani et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: A randomized, phase II, placebo-controlled trial J Clin Oncol 21 4 2003 679-689